Side-by-side comparison of AI visibility scores, market position, and capabilities
Eindhoven Netherlands automotive semiconductor leader (NASDAQ: NXPI) ~$12.6B FY2024 revenue; 60%+ automotive, S32 SDV domain controllers, UWB digital key, radar ICs competing with Infineon and Renesas.
NXP Semiconductors N.V. is a Eindhoven, Netherlands-based semiconductor company — publicly traded on the NASDAQ (NASDAQ: NXPI) as an S&P 500 Information Technology component, incorporated in the Netherlands — designing and selling mixed-signal semiconductor solutions for automotive electronics (the largest segment), smart home and industrial IoT, mobile communications security, and network infrastructure through approximately 34,000 employees in 30+ countries. NXP originated as Philips Semiconductors in 2006 when Philips divested its semiconductor division to a private equity consortium (KKR, Bain Capital, Silver Lake, Apax Partners) that took NXP public on NASDAQ in 2010, and it subsequently acquired Freescale Semiconductor in 2015 ($11.8 billion — combining NXP's security, automotive body, and RF expertise with Freescale's automotive microcontroller and analog strengths) to create the leading automotive semiconductor company by revenue. In fiscal year 2024, NXP reported revenues of approximately $12.6 billion (down from the 2022 peak as automotive semiconductor inventory destocking reduced OEM purchase orders through 2023-2024), with the Automotive segment (60%+ of revenue) generating $7.5B from vehicle electrification, ADAS, in-vehicle networking, and vehicle access systems. CEO Kurt Sievers' strategy focuses on automotive content growth: NXP's S32 automotive SoC (system-on-chip) family for domain controllers, S32G networking processors for vehicle Ethernet gateways, and SAF radar processors for advanced driver assistance systems position NXP as the preferred automotive semiconductor partner for the software-defined vehicle (SDV) transition.
Global pharma company with $55B 2024 revenue; successfully diversifying beyond Humira with Skyrizi, Rinvoq, and $8.7B Cerevel neuroscience acquisition.
AbbVie is a global research-based biopharmaceutical company focused on developing treatments for complex and serious diseases including immunology, oncology, neuroscience, aesthetics, and eye care. Spun off from Abbott Laboratories in 2013 and headquartered in North Chicago, Illinois, AbbVie rapidly became one of the world's top pharmaceutical companies on the strength of Humira — the world's best-selling drug for over a decade with peak annual sales exceeding $20 billion. AbbVie is listed on the NYSE and is a component of the S&P 500 and Dow Jones Industrial Average.
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.